Ratings Nanexa AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:07:20 03/05/2024 BST			5-day change	1st Jan Change
0.688 ^SEK	-0.86%		+13.53%	-44.07%

05-03	Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's attractive earnings multiples are brought to light by a P/E ratio at 17.2 for the current year.
The company shows low valuation levels, with an enterprise value at 0.39 times its sales.
The company appears to be poorly valued given its net asset value.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Low profitability weakens the company.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The group usually releases earnings worse than estimated.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NANEXA AB	-44.07%	8.64M		-
SEDANA MEDICAL AB	-1.99%	209M		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality